Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
325
resultados
Última actualización
11/09/2026 [07:55:00]
Resultados 75 a 100 de 325
Resumen de: AU2026210844A1
The disclosure relates to methods of diagnosis and prognosis, compositions for immunotherapies, methods of improving said compositions, and immunotherapies using the same (e.g., T cells, non- T cells, TCR-based therapies, CAR-based therapies, bispecific T-cell engagers (BiTEs), and/or immune checkpoint blockade). ul u l
Resumen de: US20260243777A1
0000 The present disclosure provides a range of compositions and methods for enriching subsets of complex biological samples. Aspects of the present disclosure provide peptide-functionalized particles comprising affinities for subsets of biomolecules from complex biological samples. The present disclosure further provides methods for utilizing functionalized particles to fractionate and analyze complex biological samples.
Resumen de: WO2026173983A1
The present invention provides methods and biomarkers useful for detecting, diagnosing and treating Alzheimer's Disease. The biomarkers for diagnoses may be used to develop treatment plans for subjects. The methods may be used to diagnose a subject prior to clinical onset of symptoms and may allow for early treatment which may slow progression of the disease.
Resumen de: WO2026174301A1
The present disclosure relates to compositions and methods for regulating lipokines in age-related disorders and methods of use thereof.
Resumen de: WO2026172292A1
The disclosed multiple-sample lateral flow system, device and method leverages multiple biological samples, lateral flow test and communication module (such as Bluetooth) for accurately detecting biomarkers related to one or more medical conditions. The multiple-sample lateral flow system comprises an integrated multiple test strip (IMTS) and device. The IMTS, configured to receive and process at least two biological samples, comprises first and second test zones configured to detect first and second sets of biomarkers specific to first and second biological samples that are indicative of at least one first medical condition, second medical condition. The device comprises a strip receiving unit to receive the integrated multiple test strip; an imaging sensor configured to capture images of the integrated multiple test strip; and a communication module configured to transmit the captured images to a processing unit for analysis and identification of the one or more medical conditions.
Resumen de: WO2026171791A1
The disclosure relates to a system for multiplex detection of analytes by primary translatable complexes. This refers to complexes of an antigen-specific primary antibody and oligonucleotides are used to detect multiple antigens of interest in a simultaneous manner. The linkage between primary antibody and oligonucleotides is achieved by using avidin-biotin system. Each of the multiple complexes are formed in individual reaction tubes and added simultaneously to biological specimens. The presence of antigens can be identified via various options using complementary oligonucleotides. This allows a simultaneous detection of analytes.
Resumen de: US20260243762A1
0000 A multimodal lateral flow assay (LFA) system for non-invasive biomarker monitoring is provided. The system includes a multimodal LFA strip having a sample-loading region for receiving a biological sample, a conjugate region containing triple-mode probes, and a membrane zone with immobilized capture and secondary antibodies that form respective test and control lines upon binding the probes. The triple-mode probes generate colorimetric, fluorescence, and surface-enhanced Raman scattering (SERS) signals. A laser-emitting module illuminates the membrane zone to excite fluorescence and SERS responses, which are detected by one or more optical detection devices. A processor performs multimodal signal mapping by analyzing fluorescence and SERS outputs to determine the quantitative concentration of the biomarker in the sample. The system enables sensitive, quantitative, and non-invasive detection of biomarkers across multiple optical modalities.
Resumen de: WO2026170288A1
Various embodiments of a wearable device for disease detection are described herein. The wearable devices include a plurality of layers including an adhesive layer for affixing the wearable device to a subject's skin and a plurality of patterned layers, each patterned layer having a sensing pattern defined thereon. When the patterned layers are assembled, the sensing patterns cooperate to define: inlet chambers adapted to receive sweat droplets, each inlet chamber having antibodies conjugated to a detection medium adapted to bind to a corresponding biomarker of interest in the sweat droplets, sensing chambers, each sensing chamber receiving the sweat droplets from at least one inlet chamber via a microchannel through capillary action and adapted to sense a corresponding biomarker of interest by binding at least a portion of the conjugate molecules associated with the corresponding biomarker, and a control chamber in fluid communication with the sensing chambers via outlet channels.
Resumen de: US20260243781A1
A method of measuring oxidative stress in a cell or tissue sample, the method including the steps of: (i) treating the cell or tissue sample in a medium; (ii) collecting a portion of the medium; (iii) measuring amounts of glutathione in the cell or tissue sample; and (iv) measuring amounts of reactive oxygen species (ROS) in the media portion collected in step (ii), step (iii) being carried out immediately after steps (i) and (ii), and step (iv) being carried out simultaneously with step (iii) or within 6 hours of step (iii) including assay time if the collected media portion is stored at about 0-8° C. until step (iv) is carried out.
Resumen de: WO2021089651A1
The current application relates to personalised nutrition methods, particularly to methods of determining whether a human subject would benefit from taking a urolithin supplement and methods for determining the treatment dose of a urolithin supplement for a human subject. Particularly methods comprising determining the level of urolithin or a urolithin conjugate in a biological fluid, such as a dried whole blood spot sample, a dried plasma spot, a m spot sample or a urine sample The current application also relates to systems for presenting whether a human subject would benefit from taking a urolithin supplement and for presenting the treatment dose of a urolithin supplement for a human subject. The current application also relates to computer implementation of methods of the invention.
Resumen de: WO2025080894A1
In one aspect, the present disclosure provides a method of detecting a presence or absence of a biomarker for a disease in the sample, wherein the biomarker comprises: a) a complex of physiologically active target macromolecules or a fragment or portion thereof and target macromolecules that are not physiologically active; b) a conformation of the physiologically active macromolecules or fragment thereof when the physiologically active target macromolecules or the fragment or portion thereof is a complex with a non- physiologically active target macromolecule; c) the conformation of physiologically active target macromolecules or a portion or fragment thereof in a PAT-Tau complex; d) the conformation of non-physiologically active target macromolecules or a portion or fragment thereof in a PAT-Tau complex; or e) a combination of a), b), c), d) and/or e).
Resumen de: EP4793283A1
The present invention belongs the field of biomedicine, namely, treating and preventing Parkinson's and Alzheimer's diseases. These diseases are characterized by the presence of amyloid fibrils that drive the pathology progression in the brains of affected individuals. The invention discloses peptides that block ends of amyloid fibrils and stop their growth.
Resumen de: WO2025027065A1
The application discloses selective chimeric chemokines and their use for selectively targeting atypical chemokine receptor 2 (ACKR2) in the treatment of an autoimmune, inflammatory, neurological, cardiovascular or proliferative disease or disorder in a subject and/or for use in improving the response of a subject to anticancer immunotherapy. The application further discloses pharmaceutical compositions comprising such selective chimeric chemokines and further provides methods of production and uses of said chimeric cytokines.
Resumen de: WO2025076635A1
Described herein are anti-alpha-synuclein antibodies. More specifically, described herein are antibodies specific to serine 129 phosphorylated alpha-synuclein. Further described herein is the use of the anti alpha-synuclein antibodies for the treatment or diagnosis of a synucleinopathy. Further described are kits and compositions comprising the anti alpha-synuclein antibodies detecting alpha-synuclein in a sample.
Resumen de: PH12017502153A1
The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.
Resumen de: CN122588234A
本发明公开了一种用于阿尔茨海默病诊断的生物标志物组合及其检测试剂盒，涉及生物医学及分子诊断技术领域，所述生物标志物组合包括检测以下基因或其编码蛋白的表达水平的试剂：胶质纤维酸性蛋白基因 GFAP、前蛋白转化酶1基因 PCSK1、可溶性耐药相关钙结合蛋白基因 SRI、SWI/SNF染色质重塑复合物亚基C1基因 SMARCC1、双特异性酪氨酸磷酸化调节激酶2基因 DYRK2 和神经肽Y基因 NPY。本发明的生物标志物组合不仅可在脑组织样本中实现有效检测，还可在外周血、血浆、血清或脑脊液等临床易于获取的样本中稳定检出，为阿尔茨海默病的大规模人群筛查和早期辅助诊断提供了一种无创、简便且易于推广的检测方案。
Resumen de: CN122587066A
本申请公开了一种用于磷酸化Tau蛋白pTau181检测的抗体、免疫检测方法及应用。本申请抗体包括T181‑1B4抗体；T181‑1B4的轻链CDR1、CDR2和CDR3依序为SEQ ID NO.1至3所示序列，重链CDR1、CDR2和CDR3依序为SEQ ID NO.4至6所示序列。基于本申请抗体对磷酸化Tau蛋白pTau181进行免疫检测，操作简单、灵敏度高、特异性强，可实现磷酸化Tau蛋白pTau181快速检测，对评估Tau蛋白磷酸化水平和Tau蛋白pTau181磷酸化相关检测具有重要意义。
Resumen de: CN122591958A
0001 本发明提供了Tau蛋白免疫传感器及其制备方法，其中，Tau蛋白免疫传感器的制备方法包括：使锰掺杂二硫化钼与金源以获得金纳米粒子‑锰掺杂二硫化钼复合体；使含有所述金纳米粒子‑锰掺杂二硫化钼复合体的悬浮液覆盖丝网印刷电极上，以在所述丝网印刷电极的表面形成复合体层；S3：在所述复合体层上覆盖抗Tau蛋白抗体溶液并孵育至少1小时，然后洗去多余抗Tau蛋白抗体溶液，得到抗Tau蛋白抗体层；及S4：封闭抗Tau蛋白抗体层上的非特异性结合位点，得到所述Tau蛋白检测传感器。根据试验确定，本发明构建的Tau蛋白免疫传感器的检测限可以低至20fM。
Resumen de: JP2026132804A
0001 【課題】神経変性疾患の診断を補助する方法、およびアルツハイマー型認知症とパーキンソン病の鑑別を補助する方法；神経変性疾患の診断キット、およびアルツハイマー型認知症とパーキンソン病の鑑別キット；並びに神経変性疾患の診断用バイオマーカー、神経変性疾患の診断用バイオマーカーセット、およびアルツハイマー型認知症とパーキンソン病の鑑別用バイオマーカーセットを提供すること。 【解決手段】被検試料中の、細胞外小胞におけるＣＤ４１の量またはＣＤ６１の量を検出することを含む神経変性疾患の診断を補助する方法であって、上記ＣＤ４１の量またはＣＤ６１の量を含む指標が、神経変性疾患以外の対象よりも低いことが、神経変性疾患を示唆する、神経変性疾患の診断を補助する方法。 【選択図】なし
Resumen de: WO2021195768A1
An aqueous stabilizing composition for preserving a bodily fluid at ambient temperature is provided. The aqueous stabilizing composition comprises: a sugar selected from a monosaccharide, a disaccharide, or a combination thereof; a buffering agent; a C1-C6 alkanol; boric acid, a salt of boric acid, or a combination thereof; and a chelating agent; wherein the composition has a pH of from 4.5 to 5.2. A method for preserving a bodily fluid using the aqueous stabilizing composition is also provided, the method comprising: a) obtaining a sample of the bodily fluid; b) contacting the bodily fluid with the aqueous stabilizing composition to form a mixture; c) mixing the mixture of (b) to form a homogeneous mixture; and d) storing the homogeneous mixture at ambient temperature.
Resumen de: CN122567800A
0001 本发明涉及一种自供电光电化学免疫传感平台及其制备方法和应用，属于光电化学生物传感器技术领域。所述传感平台包括光电阴极和光电阳极，所述光电阴极包括第一FTO导电基底和位于所述导电基底表面的NU66/T‑D‑COF复合光阴极材料，所述NU66/T‑D‑COF复合光阴极材料表面依次固定有Aβ捕获抗体和牛血清白蛋白封闭层；所述光电阳极包括第二FTO导电基底和位于所述导电基底表面的NCS@ZIS复合光阳极材料。本发明提供的传感平台能够解决传统自供电平台检测淀粉β样蛋白过程中存在的基质干扰强、光电转换效率低、信号放大能力有限的技术问题，为AD早期诊断提供高灵敏、抗干扰的自供电检测新策略。
Resumen de: CN122568008A
0001 本发明提供一种阿尔茨海默症标志物P‑tau181的单分子检测方法，属于生物技术领域。该方法包括：制备由捕获抗体包被的酶标板；制备由检测抗体包被的荧光颗粒；利用酶标板捕获目标蛋白P‑tau181；利用荧光颗粒进行荧光信号放大；利用显微荧光成像系统进行数字化成像与分析。本发明采用50‑300nm荧光颗粒实现高效信号放大，结合免液路显微成像系统进行单分子计数，检测限低至150fg/mL，R<2>=0.9996。本发明具有灵敏度高、仪器成本低、中高通量、操作简便、可视性好等优点，适用于阿尔茨海默症的大规模早期筛查、预警、临床辅助诊断及长期监测。
Resumen de: CN122562948A
0001 本发明提供了一种靶向JUN转录因子的单克隆抗体及其制备方法和应用。具体地，本发明提供了靶向JUN转录因子的抗体或其抗原结合片段，还提供了编码所述抗体或其抗原结合片段的编码序列、相应的表达载体和能够表达该抗体或其抗原结合片段的宿主细胞。本发明的靶向的单克隆抗体在多种应用场景中，能够精准识别内源性的JUN蛋白，可用于JUN检测试剂、试剂盒的制备。
Resumen de: CN122568014A
0001 本发明公开了检测P‑选择素的试剂在制备辅助诊断青光眼的产品中的应用，涉及青光眼辅助诊断技术领域。与健康对照组相比，青光眼患者血浆中P‑选择素水平显著升高，且在原发性开角型青光眼和原发性闭角型青光眼患者中同样表现出P‑选择素水平显著升高。不同疾病严重程度的患者血浆中的P‑选择素水平与健康对照组相比表现出P‑选择素水平显著升高。P‑选择素浓度对区分健康对照者与青光眼患者具有良好的鉴别效能，本发明为青光眼的辅助诊断提供了一种新的选择。
Nº publicación: KR20260123823A 14/08/2026
Solicitante:
이화여자대학교산학협력단
Resumen de: KR20260123823A
본 발명은 생물학적 시료에서 CXCL13 발현수준을 측정할 수 있는 제제를 포함하는, 염증노화(inflammaging) 진단용 조성물, 키트 및 염증노화(inflammaging) 진단에 필요한 정보를 제공하는 방법에 관한 것이다.
BOPI
Sede Electrónica
